Research

Excess omega-3 fatty acids could lead to negative health effects

A new review suggests that omega-3 fatty acids taken in excess could have unintended health consequences in certain situations, and that dietary standards based on the best available evidence need to be established. "What looked like a slam dunk a few years ago may not be as clear cut as we thought," said Norman Hord, associate professor in OSU's College of Public Health and Human Sciences and a coauthor on the paper.

"We are seeing the potential for negative effects at really high levels of omega-3 fatty acid consumption. Because we lack valid biomarkers for exposure and knowledge of who might be at risk if consuming excessive amounts, it isn’t possible to determine an upper limit at this time."

Previous research led by Michigan State University's Jenifer Fenton and her collaborators found that feeding mice large amounts of dietary omega-3 fatty acids led to increased risk of colitis and immune alteration. Those results were published in Cancer Research in 2010.

As a follow-up, in the current issue of the journal Prostaglandins, Leukotrienes & Essential Fatty Acids, Fenton and her co-authors, including Hord, reviewed the literature and discuss the potential adverse health outcomes that could result from excess consumption of omega-3 fatty acids.

Studies have shown that omega-3s, also known as long chain polyunsaturated fatty acids (LCPUFAs), are associated with lower risk of sudden cardiac death and other cardiovascular disease outcomes.

"We were inspired to review the literature based on our findings after recent publications showed increased risk of advanced prostate cancer and atrial fibrillation in those with high blood levels of LCPUFAs," Fenton said.

Omega-3 fatty acids have anti-inflammatory properties, which is one of the reasons they can be beneficial to heart health and inflammatory issues. However, the researchers said excess amounts of omega-3 fatty acids can alter immune function sometimes in ways that may lead to a dysfunctional immune response to a viral or bacterial infection.

"The dysfunctional immune response to excessive omega-3 fatty acid consumption can affect the body's ability to fight microbial pathogens, like bacteria," Hord said.

Generally, the researchers point out that the amounts of fish oil used in most studies are typically above what one could consume from foods or usual dosage of a dietary supplement. However, an increasing amount of products, such as eggs, bread, butters, oils and orange juice, are being "fortified" with omega-3s. Hord said this fortified food, coupled with fish oil supplement use, increases the potential for consuming these high levels.

"Overall, we support the dietary recommendations from the American Heart Association to eat fish, particularly fatty fish like salmon, mackerel, lake trout or sardines, at least two times a week, and for those at risk of coronary artery disease to talk to their doctor about supplements," he said.

"Our main concern here is the hyper-supplemented individual, who may be taking high-dose omega-3 supplements and eating four to five omega-3-enriched foods per day," Hord added. "This could potentially get someone to an excessive amount. As our paper indicates, there may be subgroups of those who may be at risk from consuming excess amounts of these fatty acids."

Hord said there are no evidence-based standards for omega-3 intake and no way to tell who might be at health risk if they consume too high a level of these fatty acids.

"We're not against using fish oil supplements appropriately, but there is a potential for risk," Hord said. "As is all true with any nutrient, taking too much can have negative effects. We need to establish clear biomarkers through clinical trials. This is necessary in order for us to know who is eating adequate amounts of these nutrients and who may be deficient or eating too much.

"Until we establish valid biomarkers of omega-3 exposure, making good evidence-based dietary recommendations across potential dietary exposure ranges will not be possible."

Sanjoy Ghosh from University of BC-Okanagan, Canada and Eric Gurzell from Michigan State University also contributed to this study, which was supported by grants from the National Institutes of Health and the Canadian Diabetes Association.

Most Popular Now

New particle can track chemo

Tracking the path of chemotherapy drugs in real time and at a cellular level could revolutionize cancer care and help doctors sort out why two patients might respond diff...

Read more

The effects of the Trans-Pacific Pa…

The Trans-Pacific Partnership (TPP) is a multi-national trade agreement now being considered by 12 countries. In an insightful commentary in Research in Social and Admini...

Read more

Global pharmaceutical industry call…

More than 80 leading international pharmaceutical, generics, diagnostics and biotechnology companies, as well as key industry bodies, have come together to call on govern...

Read more

Human medicines: highlights of 2015

The European Medicines Agency (EMA) has released an overview of its 2015 key recommendations in relation to the marketing authorisations of new medicines and the safety m...

Read more

Merck announces new biopharma heads…

Merck, a leading science and technology company, today announced two appointments in two regions important for its biopharma business. Gary Zieziula will lead Merck's bio...

Read more

Leading medical journals propose ma…

The International Committee of Medical Journal Editors (ICMJE) proposes new rules that will require authors to share clinical trial data as a prerequisite for their manus...

Read more

Boehringer Ingelheim and Arena Phar…

Boehringer Ingelheim and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) have signed an exclusive agreement to conduct joint research to identify drug candidates targeting an ...

Read more

Merck launches Vivera in Latin Amer…

Merck, a leading science and technology company, today announced the launch of its new consumer brand Vivera® in Latin America. Vivera is being launched first in Chile in...

Read more

New drug could be safer, non-addict…

Researchers at Tulane University and Southeast Louisiana Veterans Health Care System have developed a painkiller that is as strong as morphine but isn't likely to be addi...

Read more

European Commission confirms CMDh r…

The European Commission (EC) has taken an EU-wide legally binding decision and confirmed the favorable benefit/risk profile of ambroxol and bromhexine containing medicine...

Read more

FDA approves first drug to show sur…

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue...

Read more

Ancient medicinal clay shows promis…

Naturally occurring clay from British Columbia, Canada - long used by the region's Heiltsuk First Nation for its healing potential - exhibits potent antibacterial activit...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]